A phase 3 trial on clazakizumab in patients with chronic active antibody-mediated rejection after kidney transplantation did not meet primary efficacy outcomes and was stopped early. The study aimed to recruit 350 participants but was halted following an interim analysis showing no significant difference between clazakizumab and placebo in kidney function. The trial, which had been the first in transplantation to use a new endpoint accepted by the FDA, did not show safety concerns. Despite the disappointing results, researchers are committed to continuing research to address the needs of kidney transplant patients. The findings will be presented at ASN Kidney Week 2024.
Source link
Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR
